Royalty Report: Drugs, HIV / AIDs, Therapeutic – Collection: 329237

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 6

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6

Primary Industries

  • Drugs
  • HIV / AIDs
  • Therapeutic
  • Gastrointestinal
  • Pain
  • Respiratory

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 329237

License Grant
Pursuant to which the Company sold to Licensor a royalty interest entitling Licensor to receive future royalties on sales of Mytesi® (crofelemer).
License Property
Mytesi® (crofelemer), a Napo drug product for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Field of Use
Field of use is for the treatment diarrhea from HIV/AIDS on antiretroviral therapy.

IPSCIO Record ID: 189370

License Grant
Licensee entered into a royalty agreement with Licensor whereby it agreed to pay Licensor royalties on crofelemer in western territories. This agreement was to remain in effect until such time as Licensee is no longer receiving royalties from the sale of crofelemer products in western territories.
License Property
Crofelemer is an active pharmaceutical ingredient in Mytesi which is a human drug for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 365949

License Grant
Licensor hereby grants to Italian Licensee
(a)  an exclusive (even as to Licensor), perpetual non-transferable license, with right to grant and authorize sublicenses solely under the Licensed IP and the Licensor Trademarks for Licensee to Develop and Commercialize Products in the Licensee Territory; and;  (b)  a non-exclusive, non-transferable license, with right to grant and authorize sublicenses (to a contract manufacturer only) solely under the Licensed IP for Licensee to Manufacture or have Manufactured Products for Commercialization in the Licensee Territory, including the right to Manufacture Crofelemer and Lechlemer; provided, however, that during the Term, Licensee shall only be entitled to utilize its license to Manufacture or have Manufactured Products to the extent provided.
License Property
Licensed Patents means collectively the Tier A Patents, the Tier B Patents for which Licensee has exercised its Tier B Option in accordance with this agreement and Tier C Patents for which Licensee has exercised its Tier C Option in accordance with this agreement.

US 8,962,680 – Methods and compositions for treating HIV-associated diarrhea
US 9,585,868 – Methods and compositions for treating HIV-associated diarrhea
US 8,846,113 – Method for treatment of diarrhea-predominant irritable bowel syndrome

Field of Use
Field of use is for the treatment of cancer, Irritable bowel syndrome and other diarrhea related conditions.

Crofelemer  is a naturally occurring botanical biopolymer extracted from the stem bark latex of the Croton lechleri tree. 1 It is an FDA-approved drug for the treatment of noninfectious diarrhea in adult patients with HIV/AIDS undergoing antiretroviral therapies and acts by inhibiting 2 chloride channels located in the gastrointestinal tract.

IPSCIO Record ID: 210017

License Grant
The Licensor entered into a license agreement with the China Licensee for the development of crofelemer for the indications of HIV/AIDS diarrhea, pediatric diarrhea and adult acute infectious diarrhea.
License Property
The Licensor focuses on the development and commercialization of proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Field of Use
The China Licensee will strive to develop crofelemer for any indications in its licensed territory.

IPSCIO Record ID: 332244

License Grant
Licensor hereby grants to Licensee an exclusive (including with regard to Licensor and its Affiliates), royalty-bearing license, with the right to grant sublicenses in accordance with this Agreement, under the Licensor Technology, to Exploit the Licensed Compound or the Licensed Products in (a) the Human Excluding HIV/AIDS/ID/Pediatric Field in the Licensee Human Excluding HIV/AIDS/ID/Pediatric Territory; (b) the HIV/AIDS/Pediatric Field in the Licensee HIV/AIDS/Pediatric Territory; and (c) the ID Field in the Licensee ID Territory.

Licensor hereby grants to Licensee an exclusive (including with regard to Licensor and its Affiliates), royalty-bearing license and right of reference, with the right to grant sublicenses and further rights of reference in accordance with this Agreement, under the Regulatory Documentation Controlled by Licensor or any of its Affiliates, if any, to Exploit the Licensed Compound or the Licensed Products in (a) the Human Excluding HIV/AIDS/ID/Pediatric Field in the Licensee Human Excluding HIV/AIDS/ID/Pediatric Territory; (b) the HIV/AIDS/Pediatric Field in the Licensee HIV/AIDS/Pediatric Territory; and (c) the ID Field in the Licensee ID Territory.

Licensor hereby grants to Licensee a non-exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses in accordance with this Agreement, to use the Product Trademarks (to the extent Controlled by Licensor) as necessary to exercise its rights under the grants in this Agreement, provided that Licensor shall have a right to monitor and comment upon the manner in which such Product Trademarks are used.

License Property
Licensed Compound means oligomeric proanthocyanidin (OPC) of varying chain lengths with an average molecular weight of approximately 2000 daltons (Crofelemer), including any Improvements thereto.

Licensed Product means any form or dosage of pharmaceutical composition or preparation in finished form labeled and packaged for sale by prescription, over-the-counter, dietary supplement, food or any other method that contains the Licensed Compound as an active ingredient (including a Licensed Product that contains the Licensed Compound as an active ingredient together with one or more other active ingredients (which may be either combined in a single formulation or bundled with separate formulations but sold as one product)), and any Improvements thereto.

Patents
5,211,944 – Proanthocyanidin polymers having antiviral activity and methods of obtaining same
5,494,661 – Methods for using proanthocyanidin polymers having antiviral activity
7,341,744 – Method of treating secretory diarrhea with enteric formulations of proanthocyanidin polymer

Product Trademarks shall mean all Trademarks for use with a Licensed Product designated in accordance with this Agreement and any registrations thereof or any pending applications relating thereto.

Trademark shall include any word, name, symbol, color, designation or device or any combination thereof, including any trademark, trade dress, brand mark, trade name, brand name, logo or business symbol, which in each case is specific to a Licensed Product. Notwithstanding anything in the foregoing, the term “Trademark” does not include any house marks, trade dress or logos of Licensee or its Affiliates.

Field of Use
Licensee is investigating crofelemer in a Phase III study as an anti-secretory anti-diarrheal agent for the treatment of chronic diarrhea in people living with HIV, or HIV-associated diarrhea

Human Excluding HIV/AIDS/ID/Pediatric Field means all indications of the Licensed Compound for human use or consumption (including by way of food or dietary supplements), other than HIV/AIDS-related diarrhea, acute infectious diarrhea and pediatric diarrhea of any etiology including cholera; HIV/AIDS/Pediatric Field means only those indications of the Licensed Compound for human use for HIV/AIDS-related diarrhea and pediatric diarrhea; and ID Field means only those indications of the Licensed Compound for human use for acute infectious diarrhea, specifically including cholera and traveler’s diarrhea. This also includes the ID Field and the  HIV/AIDS/Pediatric Field.

IPSCIO Record ID: 385375

License Grant
Licensee has been granted a worldwide licence to certain Licensor patents relating to dolutegravir and a covenant not to enforce any patents controlled by Licensor against Licensee in connection with any past or future claims of infringement relating to Biktarvy. Licensor have also agreed not to enforce their patents against any future product containing bictegravir, to the extent that the patent enforcement relates to the bictegravir component of the product.
License Property
U.S. Patent No. 8,129,385 – Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness

Dolutegravir, an antiretroviral medication used, together with other medicines, to treat human immunodeficiency virus (HIV).

Biktarvy is a triple combination HIV medicine containing the HIV integrase inhibitor bictegravir, tenofovir alafenamide and emtricitabine.

Field of Use
The rights granted are for the treatment of HIV (human immunodeficiency virus).
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.